

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 August 2003 (07.08.2003)

PCT

(10) International Publication Number
WO 03/064473 A2

(51) International Patent Classification⁷: **C07K 16/00**

(21) International Application Number: PCT/IT03/00032

(22) International Filing Date: 29 January 2003 (29.01.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
RM2002A000049 30 January 2002 (30.01.2002) IT

(71) Applicant and

(72) Inventor: **BURIONI, Roberto** [IT/IT]; Piazza Ferrari, 22,
I-47900 Rimini (IT).

(74) Agents: **CAPASSO, Olga** et al.; De Simone & Partners
S.p.A., Via V. Bellini, 20, I-00198 Roma (IT).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,
SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HUMAN MONOCLONAL ANTIBODY FAB FRAGMENTS DIRECTED AGAINST HCV E2 GLYCOPROTEIN AND ENDOWED WITH IN VITRO NEUTRALIZING ACTIVITY

(57) Abstract: The invention refers to a human antibody, or its functional fragments, directed against the HCV E2 glycoprotein, able to have a neutralizing activity in vivo; a composition for anti-HCV therapy comprising in a therapeutically effective amount the antibody; a composition for topical use in gel, creme, ointment and ovule formulations; the use of the antibody for validating anti-HCV vaccines.



WO 03/064473 A2

HUMAN MONOCLONAL ANTIBODY FAB FRAGMENTS DIRECTED
AGAINST HCV E2 GLYCOPROTEIN AND ENDOWED WITH *IN VITRO*
NEUTRALIZING ACTIVITY

5 The invention concerns human monoclonal antibody Fab fragments
directed against HCV E2 glycoprotein and endowed with *in vitro*
neutralizing activity. Hepatitis C virus (VCV) infects about 4% of the world
population (World Health Organization, 1999). Over 80% of subjects
coming into contact with this pathogen develop a chronic infection as the
10 host immune response is unable to eradicate the infection, with the risk of
severe liver diseases such as chronic hepatitis, cirrhosis and liver cell
carcinoma [1, 2].

Treatment of chronic infection is based on combined therapy with
interferon and ribavirin, which is extremely costly causes major side effects
15 and is moderately effective (only 1 patient in 4 obtains long-term results)
[3, 4]. The viral infection does not provide immune protection. This fact,
together with the virus's high variability in antigenic structure recognized
by the immune system, has hindered the development of an effective
serum therapy and vaccines to protect individuals against HCV infection. It
20 is therefore clear that new antiviral strategies are strongly needed.

The author has cloned the genes coding for a large number of human
Fabs antibody fragments directed against one of the HCV proteins, the
external E2 glycoprotein, considered the most important target for immune
protective response [5]. However, the evaluation of the biological activity
25 of these antibody fragments is not simple, as no reliable *in vitro* systems
are available to determine the neutralizing activity against HCV. Hence,
the author has only evaluated and described the variable ability of different
Fabs to inhibit the binding of protein E2 to the target cell, without
demonstrating a correlation between this activity and the neutralizing
30 activity of the sera [5].

In a previous work, Burioni et al. (2001) [6], showed that some anti-E2
antibodies produced by HCV-infected patients have a negative effect,
rendering the virus less sensitive to host immune response, probably due

to its binding to the E2 antigen and to modifications of its conformation [6]. This could explain why high anti-E2 antibody titers are not directly correlated with protection against HCV infection.

5 Bugli et al., 2001 [7] generated a map of E2 protein epitopes that can bind *in vitro* the panel of anti-E2 human Fabs, showing four discrete regions against which immune response is directed (Fig. 2) [7]. The presence of antibodies directed against one or more of these regions in the serum of chronically infected patients could be associated with complications, reduced effectiveness of treatment and a different prognosis. It is therefore
10 evident that there is a need for a method to determine antibodies in a biological fluid directed against different epitopes of the HCV E2 protein. An embodiment of the present invention provides this method.

The authors of the invention have also evaluated the neutralizing activity of various anti-E2 antibodies in a system of viral pseudotypes, i.e. viruses
15 externally identical to HCV but, after entering the target cells which are able to produce a protein that produces fluorescence [8]. By revealing the presence or absence of fluorescence in the cells, the method provides a direct measure of the *in vivo* neutralizing activity of anti-E2 antibodies directed against different epitopes.

20 Unexpectedly, the authors found that two of the assayed antibodies, e137 and e301, can neutralize the virus at concentrations obtainable with a single parenteral administration of an antibody preparation; two other antibodies had no neutralizing activity and one was even able to promote viral infection.

25 The development of the method of titering different antibody populations in a patient represents a valuable diagnostic and prognostic instrument with the potential to distinguish between affected subjects at risk for developing severe complications and those with a more favorable prognosis. In this latter group, this method would eliminate the need to administer a largely
30 ineffective treatment that is also associated with severe side effects, while providing a considerable reduction in costs.

As the E2 epitopes, so identified, are not reproducible by synthesizing synthetic peptides [5], the method represents the only way to determine the amount of antibodies against the different parts of the protein E2, with correlated clinical and epidemiological data.

5 The identification of anti-E2 antibodies in the human Fabs format with a good neutralizing ability permits their large-scale production and use as a medication in anti-HCV treatment, or as a preventive agent in topical form to inhibit viral transmission to subjects at risk (couples with discordant HCV state, individuals subject to occupational exposure, etc.).

10 The antibodies of the invention can be advantageously used to evaluate *in vitro* candidate molecules for anti-HCV vaccines, i.e. able to stimulate neutralizing antibodies but not ineffective or negative antibodies.

The availability of neutralizing human antibodies able to recognize a broad spectrum of viruses could be crucial in the production of artificial vaccines.

15 The neutralizing antibodies described in this document can be used as a template for the development of vaccines (made from peptides or anti-idiotypic antibodies) able to stimulate a neutralizing cross-reactive response.

The object of this invention is a human antibody, or its functional
20 fragments, against the HCV E2 protein, endowed with an *in vivo* neutralizing activity.

In a particular embodiment, the antibody of the invention is the antibody e137, which is characterized by the following amino acid sequences of the variable part of the heavy and light chains:

25 e 137 Heavy chain (HC)

LLEQSGSEVKVPGSSLKVSCKTSGGTFSTYTFSWVRQAPGQGLEWMG
GITPIIGIANYNFQDRVTITADESTSTVYMEVRRRLRSEDTAVYYCAKTS
EVTATRGRTFFYSAMDVWGQGT

e 137 Light chain (LC)

30 MAELTQSPSFLSASVGDRVTITCRASQGISNYLAWYQQKPGKAPKLLIYA
ASTLQSGVPSRFSGSGSWTEFTLTISRLQPEDFATYYCQHLNTPWTFG
QGT

In an alternative embodiment, the antibody of the invention is the antibody e301, which is characterized by the following amino acid sequences of the variable part of the heavy and light chains:

e 301 Heavy chain (HC)

5 LLEQSGSEVKKPGSSVRVSCCTTSGGTLSDYGFNWLRQAPGQGPEWMG
GIIPLFRRTTYGQKFQGRLTITADESTGATYMESSLRSDDTAVYYCARE
KVSFLTGGKSLHYFEYWGKGT

e 301 Light chain (LC)

MAELTQSPATLSVSPGERATLSCRASQSVSSRLAWYQQKRGQAPSLLIY
10 DTSSRATGVPARFSASGSGTQFTLTISLQSEDFALYYCQQYNDWPSTF
GQGT

A further object of the invention is a composition for anti-HCV therapy comprising in a therapeutically effective amount at least one of the antibodies of the invention. Preferably, the composition is supplied in
15 purified form for parenteral use or in another formulation for topical use as a gel, creme, ointment, ovule, with excipients known to experts in the field.

A further object of the invention is a nucleic acid coding for each of the antibodies of the invention. Advantageously, the nucleic acid can be contained in an expression vector which can effectively express the
20 antibody of the invention in prokaryote or also in eukaryote cells. In a preferred form, the recombinant vector also contains a nucleotide sequence coding for a signal peptide which is substantially contiguous with the coding sequence for the antibody of the invention, and is able to export the antibody out of the cell environment.

25 A further object of the invention is the use of the recombinant vector as described in gene therapy.

The invention is described below in experimental examples, not limiting the invention itself, in reference to the following figures:

- Figure 1 FIT: THEORETICAL BASIS. Panel A shows the binding of a
30 Fab-FLAG to its epitopes without competitors. Using the same concentration of Fab present in (A), preincubation of the antigen with the patient's serum permits quantitative analysis of antibodies directed against

the epitope recognized by the Fab in the serum. In panels B and C, the bound antibodies, as they compete with Fab, proportionately diminish the amount bound compared with panel A. In panels D and E, the presence of antibodies not directed against the specific epitope does not minimally influence Fab binding.

- Figure 2 A and B: Inhibition of binding between e8-FLAG (A) and e509-FLAG (B) to HCV/E2 by sera containing known concentrations of e8-IgG1 and e509-IgG1 (whole antibodies directed against the epitopes recognized by the Fab). It is clear that the inhibition of Fab binding can be observed only in the presence of the whole antibody having the same specificity and that this depends on antibody concentration.

- Figures 3A, B and C: Inhibition of infection of VSV/HCV and VSV/G pseudotypes by purified anti-HCV/E2 human recombinant Fabs at different concentrations. HepG2 cells infected with Fab-treated pseudotypes were incubated for 16 hr and the number of green fluorescent protein-expressing cells was determined by fluorescence microscopy. Data are presented as % of the infection detected in control wells (no Fabs added). The results shown are the average of three independent assays performed in double.

- Figure 4: Two-dimensional surface-like map of the human B cell epitopes present on the surface of HCV/E2 as recognized by the monoclonal antibodies used in this study. Overlapping circles indicate reciprocal inhibition. Fabs endowed with VSV/HCV pseudotype neutralizing activity are underlined. The putative region mediating the interaction of HCV/E2 with the cellular target is indicated by the dotted line. The putative region recognized by neutralizing antibodies is indicated by a solid black circle. Due to modifications that can be induced by antigen-antibody interactions, this diagram does not correspond to the actual physical map.

EXAMPLE 1

Materials and methods

Anti-HCV Fabs and full-size IgG1 production

Generation, purification and characterization of the anti-HCV/E2 Fabs have been described elsewhere [5]. FLAG-Fabs (Fabs labeled with a FLAG epitope fused at the carboxyterminal of the heavy chain fragment with a pentapeptide bridge) were constructed and purified as described
5 elsewhere [6]. Validation and standardization of the assay were performed using Fab-coding genes to construct full-size human monoclonal antibodies (HuMabs), which were inserted in an appropriate eukaryotic vector for subsequent production in transfected cells [9]. The HuMabs present in the culture supernatant were purified by immunoaffinity as
10 described [10] and purity-checked by PAGE. The amount of human antibody was assayed by a sandwich immunoassay. All antibodies and Fabs were stored at -70°C until use.

Sera and specimens

Sera obtained from healthy donors and HCV-positive patients were
15 analyzed using commercial diagnostic kits (Ortho, Raritan, NJ) following standard procedures. For the preparation of mock specimens with known amounts of antibodies directed against a given epitope, HCV-negative sera were spiked with concentrated purified HuMabs in PBS and treated exactly like the positive and negative sera.

Design of Fab Inhibition Titer (FIT) assay

20 The purpose of this assay is to assess the ability of sera to inhibit the binding of a labeled Fab to its epitope, thus obtaining an indirect measure of the amount of epitope-binding antibodies in sera (Fig.1).

FLAG-Fabs were purified [10] and assayed in a FLAG-Fab-specific ELISA
25 to determine the correct concentration to be used in inhibition experiments. Briefly, FLAG-Fab preparations of known concentration were titrated by ELISA [11], where antigen-coated plates were blocked for 1 h at 37°C with PBS/1%BSA. After removing the blocking solution, 50 μl of progressive dilutions of FLAG-Fab made in PBS/BSA 1% were added to
30 the wells and incubated for 2 h at 37°C . Plates were washed 10 times with PBS/0.05% Tween-20 in an automated plate washer (DiaSorin, Saluggia, Italy) before adding 50 μl of a 10 $\mu\text{g/ml}$ solution of anti-FLAG mouse

monoclonal antibody M2 (Sigma, St. Louis, MO; 10 μ g/ml in PBS) in PBS/BSA 1%. After 1 h incubation at 37°C, wells were washed 10 times with PBS/Tween-20 as above and mouse monoclonal antibody binding was revealed with horseradish peroxidase-conjugated goat anti-mouse IgG (Pierce; 1:8,000 in PBS). Substrate was added and plates were read for OD₄₅₀ in an automated plate reader after 30 min incubation at room temperature in the dark. All assays were performed at least in double. A negative control antigen (BSA) was always included and the OD reading was subtracted as background.

For the determination of the Fab Inhibiting Titer (FIT) of sera, a concentration of purified FLAG-Fabs yielding in standard conditions an OD₄₅₀ reading equal to 50% of maximum reading was used for further experiments of Fab inhibition ELISA. For these experiments, plates were coated and blocked as described above. Progressive 1:4 serum dilutions in PBS/BSA 1% were added in the amount of 50 μ l per ELISA well. After 2 h of incubation at 37°C, purified FLAG-Fab was added directly to serum dilutions to reach the desired final concentration. Plates were incubated for additional 30 min and then processed as described above for FLAG-Fab ELISA. A positive control sample, containing a 20:1 excess of purified unlabeled Fab, corresponding to 100% inhibition, is included. A negative control sample, containing an excess of a control uncorrelated Fab [12] and corresponding to 0% inhibition, is also included. The final results are determined as % of inhibition with the formula: percent inhibition = 100 x (OD₄₅₀ of probe FLAG-Fab alone - OD₄₅₀ of probe FLAG-Fab with competing serum)/ OD₄₅₀ of probe FLAG-Fab alone.

The highest serum dilution giving more than 70% inhibition of FLAG-Fab binding is considered as the Fab Inhibiting Titer (FIT) for that epitope and for that serum.

Results

The appropriate FLAG-Fab concentration to be employed in the assay is determined for each FLAG-Fab and ranges from 10 μ g/ml (e8, e20, e137,

e301, e509) to 0.1 µg/ml (e10-B). The amino acid sequences of the light and heavy chains of the various antibodies are given below:

e8 HC

LLEQSGAEVKMPGATVKVSCQSSRYTFTSYGIGWVRQAPGQGLEWMG
5 WISGYTHETKYAQSFQGRVTMTAETSTGTAYMELRSLRSDDTATYYCA
RDGGGRVVVPPTHLRAFDVWGQGT

e8 LC

MAELTQSPGTLSLSPGERATLSCRASHRVNNNFLAWYQQKPGQAPRLLI
SGASTRATGIPDRFSGSGSGTDFTLTISRLEPDDFAVYYCQQYGDSPLY
10 SFGQGT

e10 HC

LLESGPGLVKPSQTLSTCTVSGVSISYGGRGVSYWGWVRQSPGKGLE
WIGHIYYFGDTFYNPSLNNRATISIDSSKNQFSLKLKSVTASDTALYFCAR
STLQYFDWLLTREAAYSIDFWGQGI

15 e10 LC

MAELTQSPSFLSASVGDRVTITCRASQGV TILLAWYQQKPGKPPKALIYA
ASSLQSGVPSRFSGSGSDTDFTLTISLQPEDSATYYCQQLNTYPWTFG
QGT

e20 HC

20 LLEQSGAEVKKPGSSVKVSCKASGDHYGINWVRQAPGQGLEWMGGIIP
VFGTTTYAQKFQGRATITADDSTGTAFLELTRLTFFDDTAVYFCATPHQLH
VLRGGKALSPWDYWGQGT

e20 LC

MAELTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKRGQAPSLLIY
25 GTSTRATGIPARFSGSGSGTEFTLTISLQSEDFAVYYCQQYNDWPSTF
GQGT

e137 HC

LLEQSGSEVKVPGSSLKVSCKTSGGTFFSTYTFSWVRQAPGQGLEWMG
GITPIIGIANYARNFQDRVITADESTSTVYMEVRRLRSED TAVYYCAKTS
30 EVTATRGRTFFYSAMDVWGQGT

e137 LC

MAELTQSPSFLSASVGDRVITICRASQGISNYLAWYQQKPGKAPKLLIYA
ASTLQSGVPSRFSGSGSWTEFTLTISRLQPEDFATYYCQHLNTPWTFG
QGT

e301 HC

5 LLEQSGSEVKKPGSSVRVSC TTSGGTLSDYGFNWLRQAPGQGPEWMG
GIPLFRRTTYGQKFQGRLTITADESTGATYMESSLRSDDTAVYYCARE
KVS VLTGGKSLHYFEYWGKGT

e301 LC

MAELTQSPATLSVSPGERATLSCRASQSVSSRLAWYQQKRGQAPSLLIY
10 DTSSRATGVPARFSASGSGTQFTLTISLQSEDFALYYCQQYNDWPSTF
GQGT

e509 HC

LLEESGAEVKKPGSSVKV SCKTSGDTFRYGITWVRQAPGQGLEWMGQI
MPTFATATYAQRFQGRVTISADESTSTAYLEVRSLRSED TAVYYCATPR
15 QVTILRGPKALSPWDYWGQGT

e509 LC

MAELTQSPATLSASPGERASLSCRASQSVSSNLAWYQQKPGQAPRLLIS
GASTRATGVPARFSGSGSGTEFTLTISLQSEDFAVYYCQQYNNWPPH
FGQGT

20 The nucleotide sequences coding for the Fab fragments listed above are
indicated as follows:

e8 HC

CTGCTCGAGCAGTCTGGAGCTGAGGTGAAGATGCCTGGGGCCACAG
TGAAGGTCTCCTGCCAGTCTTCCCGTTACACCTTCACCA GTTACGGT
25 ATCGGCTGGGTGCGACAGGCCCTGGACAGGGGCTTGAGTGGATG
GGATGGATCAGCGGATACACCCATGAGACAAAATATGCACAGAGTTT
CCAGGGCAGAGTCACCATGACCGCAGAGACATCCACGGGCACAGCG
TATATGGAGTTGAGGAGCCTGCGGTCTGACGACACGGCCACATATTA
CTGCGCGAGAGATGGAGGAGGGAGGGTGGTAGTGCCGCCTACTCAT
30 CTACGTGCTTTTGATGTCTGGGGTCAAGGGACG

e8 LC

ATGGCCGAGCTCACCCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGG
GGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCACAGAGTCAATAACA
ACTTCTTAGCCTGGTATCAGCAGAAACCTGGCCAGGCTCCCAGGCTC
CTCATCTCTGGTGCATCTACCAGGGCCACTGGCATCCCAGACAGGTT
5 CAGTGGCAGTGGGTCTGGAACAGACTTCACTCTCACCATCAGCAGAC
TGGAGCCTGATGATTTTGCAGTTTATTATTGTCAGCAGTATGGTGACT
CACCTCTTTATTCTTTTGGCCAGGGGACC

e10 HC

CTGCTCGAGTCTGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGT
10 CCCTCACCTGCACCGTCTCCGGTGTCTCCATCAGTTACGGTGGTCGT
GGCGTTTCCTACTGGGGTTGGGTCCGCCAGTCCCCAGGGAAGGGCC
TGGAGTGGATTGGCCACATCTACTACTTTGGAGACACCTTCTACAAC
CCGTCCCTCAACAATCGAGCTACCATATCAATAGACTCATCCAAAAC
CAGTTCTCCCTCAAGCTCAAGTCTGTGACTGCCTCAGACACGGCCCT
15 GTATTTCTGTGCCAGGAGCACCCCTACAGTATTTTGACTGGTTATTGAC
ACGGGAGGCTGCCTACTCCATTGACTTCTGGGGCCAGGGAATA

e10 LC

ATGGCCGAGCTCACCCAGTCTCCATCCTTCCTGTCTGCATCTGTTGG
AGACCGAGTCACCATCACTTGCCGGGCCAGTCAGGGCGTCACCATT
20 CTTTTAGCCTGGTATCAGCAAAAGCCAGGGAAACCCCCTAAGGCCCT
GATTTATGCTGCATCGTCTTTGCAAAGTGGGGTCCCATCAAGGTTCA
GCGGCAGTGGTTCTGACACAGATTTCACTCTCACAATCAGCAGCCTA
CAGCCTGAAGATTCTGCAACTTATTACTGTCAACAACCTTAACACTTAC
CCGTGGACGTTTCGGCCAGGGGACC

25 e20 HC

CTGCTCGAGCAGTCAGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGG
TGAAGGTCTCCTGCAAGGCTTCTGGAGACCACTATGGTATCAACTGG
GTGCGACAGGCCCCTGGACAAGGGCTGGAGTGGATGGGCGGTATCA
TCCCTGTCTTTGGCACAACCTACCTACGCACAGAAGTTCCAGGGCAGA
30 GCCACCATTACCGCGGACGACTCCACGGGGACGGCCTTTTTTGGAGC
TGACCAGACTGACATTTGACGACACGGCCGTCTATTTCTGTGCGACA

CCTCACCAACTGCATGTCCTCCGGGGCGGTAAAGCCCTCTCCCCCT
GGGACTACTGGGGCCAGGGAACC

e20 LC

ATGGCCGAGCTCACCCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGG
5 GGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGT
AACTTAGCCTGGTACCAGCAGAAACGTGGCCAGGCTCCCAGTCTCCT
CATCTACGGAACATCTACCAGGGGCCACTGGTATCCCAGCCAGGTTCA
GTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCT
GCAGTCTGAAGATTTTGCAGTTTATTACTGTCAGCAGTATAATGATTG
10 GCCCTCCACCTTCGGCCAAGGGACA

e137 HC

CTGCTCGAGCAGTCTGGGTCTGAAGTAAAAGTGCCCCGGGTCTCGTT
GAAGGTCTCCTGCAAGACTTCTGGAGGCACCTTCAGCACCTATACTT
TCAGCTGGGTGCGACAGGCCCTGGACAGGGACTTGAGTGGATGGG
15 GGGGATCACCCCTATCATTGGCATCGCAAACCTACGCACGGAACTTCC
AGGACAGAGTCACCATCACCGCGGACGAATCCACGAGCACGGTCTA
CATGGAGGTGAGGAGGCTGAGATCTGAGGACACGGCCGTATATTATT
GTGCGAAAACCTTCGGAAGTAACAGCCACTAGAGGGCGGACTTTCTTC
TACTCCGCTATGGACGTCTGGGGTCAAGGGACC

20 e137 LC

ATGGCCGAGCTCACCCAGTCTCCATCCTTCCTGTCTGCATCTGTAGG
AGACAGAGTCACCATCACTTGCCGGGGCCAGTCAGGGCATAAGCAATT
ATTTAGCCTGGTATCAGCAAAAACCAGGGAAAGCCCCTAAGCTCCTG
ATCTATGCTGCATCCACTTTGCAAAGTGGGGTCCCATCGAGGTTTCA
25 CGGCAGTGGATCTTGGACAGAATTCACTCTCACAATCAGCCGCCTCC
AGCCTGAAGATTTTGCAACTTATTACTGTCAACACCTTAATACTTACCC
GTGGACGTTTCGGCCAAGGGACC

e301 HC

CTGCTCGAGCAGTCTGGGTCTGAGGTGAAGAAACCTGGGTCTCGG
30 TGAGGGTCTCGTGCACGACTTCTGGAGGCACCTTGAGCGACTATGGT
TTCAACTGGTTACGACAGGCCCTGGACAAGGGCCTGAGTGGATGG
GAGGGATCATCCCTTTGTTTCGAAGAACAACCTACGGACAGAAGTTC

CAGGGCAGACTCACCATTACCGCGGACGAGTCCACGGGCGCAACCT
ACATGGAGCTGAGCAGCCTGAGATCTGACGACACGGCCGTCTATTAC
TGTGCGAGAGAGAAAGTTTCGGTCCTCACAGGCGGAAAGTCACTCCA
T TACTTTGAATATTGGGGCAAGGGAACC

5 e301 LC

ATGGCCGAGCTCACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAG
GGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAG
CAGGTTAGCCTGGTACCAGCAGAAACGTGGCCAGGCTCCCAGTCTC
CTCATCTATGACACATCTTCCAGGGCCACTGGTGTCCCAGCCAGGTT
10 CAGTGCCAGTGGGTCTGGGACGCAGTTCCTCTCACCATCAGCAGC
CTGCAGTCTGAAGATTTTGCAGTTTATTACTGTCAGCAGTATAATGATT
GGCCCTCCACCTTCGGCCAAGGGACA

e509 HC

CTGCTCGAGGAGTCTGGGGCTGAGGTGAAGAAGCCAGGGTCCTCGG
15 TGAAGGTCTCCTGCAAGACTTCTGGAGACACCTTCAGATATGGTATC
ACGTGGGTGCGACAGGCCCTGGACAAGGGCTTGAGTGGATGGGAC
AGATCATGCCTACGTTTTCGACAGCAACCTACGCACAGAGGTTCCAG
GGCAGAGTCACGATTTCCGCGGACGAATCCACGAGCACAGCCTACTT
GGAGGTGCGCAGCCTGAGATCTGAAGACACGGCCGTCTATTACTGT
20 GCGACACCTCGCCAAGTTACTATACTTCGGGGACCTAAAGCCCTCTC
CCCTTGGGACTACTGGGGCCAGGGAACC

e509 LC

ATGGCCGAGCTCACCCAGTCTCCAGCCACCCTGTCTGCGTCTCCAG
GGGAAAGAGCCTCCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGTAG
25 CAACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTC
CTCATCTCTGGTGCATCCACCAGGGCCACTGGTGTCCCGGCCAGGT
TCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGTAGC
CTGCAGTCTGAAGATTTTGCAGTTTATTACTGTCAGCAGTATAATAAC
TGGCCTCCCCACTTTGGCCAGGGGACC

30 FLAG-Fab ELISA on purified labeled Fab molecules yields very specific
and reproducible results. Determination of FIT is performed on 10 HCV-
negative sera; the titer is consistently >1:20, the upper detection limit of

our test, indicating that no inhibition occurs in the absence of specific anti-HCV antibodies.

To demonstrate that FIT effectively measures the antibodies directed against epitopes recognized by our FLAG-Fabs, the same analysis is performed on mock specimens prepared by mixing negative sera with human monoclonal antibodies of given specificity, obtaining false samples containing known amounts of IgG directed against the HCV E2 epitopes defined by our Fabs. Results (Figures 2A and B) show a good correlation between FIT and antibody amount, indicating that FIT can provide reliable information on the amount of epitope-specific antibodies in a patient's serum.

Finally, FIT is always positive in HCV-positive sera, with values encompassing a wide range of dilutions. FIT is very diverse for the different Fabs in the same serum sample, with considerable heterogeneity between patients.

EXAMPLE 2

Materials and Methods

Human antibody fragments

The human recombinant antibody fragments in this example are fully described in Bugli et al. (2001) [7] and correspond to those used in Example 1. Briefly, genes coding for the Fabs were obtained from a phage display combinatorial library containing the IgG1/kappa repertoire of a 58-year-old woman with chronic hepatitis with persistent presence in the blood of HCV RNA of genotype 1b. The genes selected are inserted in an appropriate bacterial expression vector [13] and the transformed cells are then used as a source of recombinant Fabs, which are produced and purified as described [14]. Neutralization of E2 binding to cell (NOB) activity [5, 15] and the reciprocal interactions [7] of these molecules have been described. The presence of similar antibodies in the serum of HCV-infected patients is determined by inhibition ELISA [7].

Pseudotypes and neutralization assay

The pseudotypes used here have been fully characterized and described in Matsuura et al., 2001 [8]. Briefly, the VSVΔG*/HCVE1-E2 pseudotype (VSV/HCV) consists of Vesicular Stomatitis Virus, where the G envelope protein is replaced with chimeric E1 and E2 HCV envelope glycoproteins consisting of the ectodomains of E1 and E2 proteins of type 1b HCV cDNA clone (NIH-J1) fused to the N-terminal signal sequences, with transmembrane and cytoplasmatic domains of VSV G protein [8]. The construction of plasmids [16], and eukaryotic expression vectors has been described [8, 17]. VSV/HCV is prepared by infecting CHO cells constitutively expressing chimeric E1 and E2 cDNA with a recombinant VSV in which the G protein-coding region has been replaced with the green fluorescent protein gene (GFP) [18]. The VSVΔG*/HCVE1-E2 (VSV/G) pseudotype used as control (and to produce the VSV/HCV pseudotype), is produced by infecting with VSVΔG* a cell line transiently expressing G protein. The neutralization assay is performed as described [8]. Dilutions of purified human recombinant Fabs are incubated with 2.4×10^3 Infection Units (IU) of the pseudotype VSV/HCV or VSV/G for 30 min at 37°C and inoculated into HepG2 cells (4×10^4 cells) prepared in a 96-well plate. After adsorption for 60 min at 37°C, the cells are washed 3 times with DMEM containing 10% FBS and incubated at 37°C for 16 hr. The IU of the virus are determined by counting the number of GFP-expressing cells by fluorescence microscopy. Data are presented as percent of inhibition compared with control wells where no antibody was added. Data are the average of three experiments performed in double.

25 Results

Anti-HCV/E2 human monoclonal antibody panel generation and sequence characterization

The panel of human monoclonal antibody Fab fragments represents the anti-HCV/E2 immune repertoire of a patient with a persistent infection with HCV of genotype 1b [5, 19]. Antibody fragments, selected with purified recombinant HCV/E2 of 1a genotype (strain H)[20] expressed in CHO cells, have been fully characterized and correspond to clones present in

the serum of chronically infected patients [7] with a shared equal affinity for HCV/E2. Each of the five antibodies represents one of the five families in which the whole anti-E2 antibody repertoire of this patient is grouped. Fabs belonging to the same family share similar biological activity and have strong homologies of DNA sequences [5]. Each of the five Fabs recognizes a different epitope on the surface of E2 [7]. Divergences from the relative germ-line sequences are typical of antigen-driven affinity maturation (Tables 1a and 1 b), suggesting a prolonged exposure to the antigen.

TABLES 1 A, B. Germlines and V gene mutations in variable regions of anti-HCVE2 human monoclonal antibodies.

Sequences are determined as described in Burioni et al., 1998 [5] and aligned with germline sequences in the IMGT database [21]. The percentage of nucleotide and amino acid mutations are calculated according to the Kabat and Wu alignment method [22], taking into account framework region (FR) 1, FR 2 and FR 3 for heavy and light chains, the complementarity determining region (CDR) 1 and CDR 2 for heavy chains, CDR 1, CDR 2 and CDR 3 for light chains.

Table 1 a - HEAVY CHAINS

Antibody	V gene	% of mutated nucleotides		% of mutated amino acids	
		FRs	CDRs	FRs	CDRs
e 8	VH1-18	9.5	22.2	14.9	33.3
e 20	VH1-69	9.4	16.9	19	38
e 137	VH1-69	11.5	15.3	14	41.7
e 301	VH1-69	8.9	19.4	15.6	45.8
e 509	VH1-69	5.2	15.9	10.9	33.3

Table 1 b - LIGHT CHAINS

Antibody	V gene	% of mutated nucleotides		% of mutated amino acids	
		FRs	CDRs	FRs	CDRs
e 8	KV 3-20	2.7	16	2.6	33.3
e 20	KV 1- 9	4.3	7.7	9.7	22.2
e 137	KV 1- 8	2.2	9	3.2	15.4
e 301	KV 3-15	3.8	14.3	9.7	23
e 509	KV 3-15	3.2	1.3	6.5	0

Neutralizing of binding (NOB) activity of each Fab was also determined [5], with some clones (e137 and e8) found to be unable to inhibit HCV/E2 binding to cells and others inhibiting HCV/E2 binding even at very low concentration (see below).

Neutralization of the pseudotype virus by human recombinant Fabs

Two of the Fabs, e8 and e20, recognizing different epitopes on the surface of HCV/E2 [7] do not neutralize VSV/HCV pseudotype infection even at high concentrations (80 µg/ml). One of these two Fabs, e20, has strong NOB activity [5], confirming that even antibodies inhibiting E2 binding may fail to prevent viral infection.

Two other Fabs, e137 and e301, efficiently neutralize VSV/HCV at a concentration of 10 µg/ml, while VSV pseudotypes bearing the VSV G envelope protein (VSV/G pseudotypes) are not affected (Figures 3a and 3b). These data are congruent with previous findings indicating that these two clones compete for the same E2 region, probably recognized by human antibodies endowed with neutralizing activity, as indicated in a two-dimensional surface map of the human epitopes on HCV/E2 (Figure 4).

Fab 509 is currently the strongest available antibody in terms of NOB activity, and is able to inhibit binding between E2 and the cellular target at very low concentrations (Table 2). Incubation of VSV/HCV pseudotypes

with this Fab enhance virus entry into hepatoma cells down to a concentration of 1 µg/ml. No increase in infectivity is demonstrated when VSV/G pseudotypes are used, thus ruling out the possibility that a non-specific interaction of this Fab with cellular membrane promotes viral entry into the cell (Fig.3C).

Table 2 - Anti-HCV/E2 antibodies characteristics

NOB activity is calculated as the concentration (in µg/ml) achieving 50% of neutralization of binding of a purified HCV/E2 preparation to cellular targets.

Fab clone	50% NOB concentration (µg/ml)	Effect on VSV/HCV infection
e8	>40 (none)	none
e20	3 (high)	none
e137	40 (low)	inhibition
e301	3 (high)	strong inhibition
e509	<0.035 (highest)	enhancement

A control antibody [23] exerts no effect on the pseudotype system, as it fails to neutralize both VSV/HCV and VSV/G pseudotypes. The VSV/G pseudotype is duly neutralized by dilutions up to 1:1000 of a polyclonal anti-VSV antiserum used as neutralizing control in these experiments [8], which have no effect on the VSV/HCV. Polyclonal and monoclonal anti-E1 and anti- E2 antibodies raised in several hosts show no neutralizing effect on VSV/HCV pseudotypes.

The neutralizing activity of monovalent Fabs shows that HCV entry can be inhibited without the need for virion aggregation or cross-linking; furthermore, blocking of interaction between the virus and its cellular target seems unlikely to be a key factor in HCV neutralization. These data can explain at the molecular level the lack of correlation between NOB activity in the serum and protection from disease.

Some degree of cross-protection is provided by anti-HCV antibodies, as anti-E2 antibodies selected with E2 of 1a genotype are able to neutralize a pseudotype bearing E2 of 1b genotype.

The results show that Fab 509 is able to enhance the infectivity of the VSV/HCV pseudotype virus, although no effect on the VSV/G construct was apparent. A possible explanation for the ability of e509 to promote viral entry can be found in the observation that this antibody binds specifically and very efficiently to the region of E2 that binds to CD81, a cellular structure involved in viral attachment to the cell [24]. The binding of e509 to E2 could mimic the binding of E2 to one of its cellular targets and promote a modification of E2 conformation similar to the one induced by CD81. E2 is present in at least two conformational states and antibody binding to this protein can modify the sterical status of the protein by modulating the NOB activity of human Fabs without binding competition [6]. Hence, Fab 509 seems to be a key tool for the study of the interactions between HCV and the cell surface and could be used in *in vitro* models for the evaluation of molecules for vaccines.

REFERENCES

1. Hoofnagle, *Hepatitis C: the clinical spectrum of disease*. Hepatology, 1997. **26**(3 Suppl 1): p. 15S-20S.
2. Cerny and Chisari, Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology, 1999. **30**(3): p. 595-601.
3. Fried and Hoofnagle, *Therapy of hepatitis C*. Semin Liver Dis, 1995. **15**(1): p. 82-91.
4. Hoofnagle and di Bisceglie, *The treatment of chronic viral hepatitis*. N Engl J Med, 1997. **336**(5): p. 347-56.
5. Burioni, et al., Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments. Hepatology, 1998. **28**(3): p. 810-4.
6. Burioni, et al., Non-neutralizing human antibody fragments against Hepatitis C Virus E2 Glycoprotein Modulate Neutralization of Binding Activity of Human Recombinant Fabs. Virology, 2001. **288**: p. 29-35.

7. Bugli, et al., Mapping B cell epitopes of Hepatitis C Virus E2 glycoprotein using human monoclonal antibodies from phage display libraries. *J Virol*, 2001. **75**(20): p. 9986-9990.
8. Matsuura, et al., Characterization of Pseudotype VSV possessing HCV envelope proteins. *Virology*, 2001. **286**(2): p. 263-75.
9. Bender, et al., Recombinant human antibodies: linkage of an Fab fragment from a combinatorial library to an Fc fragment for expression in mammalian cell culture. *Hum Antibodies Hybridomas*, 1993. **4**(2): p. 74-9.
10. Barbas, et al., Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity. *Proc Natl Acad Sci U S A*, 1992. **89**(21): p. 10164-8.
11. Williamson, et al., Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries [published erratum appears in *Proc Natl Acad Sci U S A* 1994 Feb 1;91(3):1193]. *Proc Natl Acad Sci U S A*, 1993. **90**(9): p. 4141-5.
12. Burioni, et al., Recombinant human Fab to glycoprotein D neutralizes infectivity and prevents cell-to-cell transmission of herpes simplex viruses 1 and 2 in vitro. *Proc Natl Acad Sci U S A*, 1994. **91**(1): p. 355-9.
13. Burioni, et al., A vector for the expression of recombinant monoclonal Fab fragments in bacteria. *J Immunol Methods*, 1998. **217**(1-2): p. 195-9.
14. Barbas, et al., Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. *Proc Natl Acad Sci U S A*, 1992. **89**(19): p. 9339-43.
15. Rosa, et al., A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. *Proc Natl Acad Sci U S A*, 1996. **93**(5): p. 1759-63.
16. Takikawa, et al., Cell fusion activity of hepatitis C virus envelope proteins. *J Virol*, 2000. **74**(11): p. 5066-74.

17. Ohashi, et al., Ligand-induced activation of chimeric receptors between the erythropoietin receptor and receptor tyrosine kinases. *Proc Natl Acad Sci U S A*, 1994. **91**(1): p. 158-62.
18. Takada, et al., A system for functional analysis of Ebola virus glycoprotein. *Proc Natl Acad Sci U S A*, 1997. **94**(26): p. 14764-9.
5
19. Plaisant, et al., Human monoclonal recombinant Fabs specific for HCV antigens obtained by repertoire cloning in phage display combinatorial vectors. *Res Virol*, 1997. **148**(2): p. 165-9.
20. Lesniewski, et al., Antibody to hepatitis C virus second envelope (HCV-E2) glycoprotein: a new marker of HCV infection closely associated with viremia. *J Med Virol*, 1995. **45**(4): p. 415-22.
10
21. Lefranc, et al., *IMGT, the international ImMunoGeneTics database*. *Nucleic Acids Res*, 1999. **27**(1): p. 209-12.
22. Kabat, *Sequences of Proteins of Immunological Interest*. 5th ed. 1991, Bethesda, MD: U.S. Department of Health and Human Services.
15
23. Burioni, et al., A new subtraction technique for molecular cloning of rare antiviral antibody specificities from phage display libraries *Res Virol*, 1998. **149**(5): p. 327-30.
24. Pileri, et al., *Binding of hepatitis C virus to CD81*. *Science*, 1998.
20 **282**(5390): p. 938-41.

CLAIMS

1. An human antibody, or its functional fragments, against the HCV E2 protein characterized in having an *in vivo* neutralizing activity.

2. Antibody according to claim 1, being the antibody e137 characterized by
5 having the following sequences of variable parts of the heavy chain and the light chain:

e 137 Heavy chain (HC)

LLEQSGSEVKVPGSSLKVSCKTSGGTFSTYTFSWVRQAPGQGLEWMG
GITPIIGIANYARNFQDRVITADESTSTVYMEVRRLRSED TAVYYCAKTS
10 EVTATRGRTFFYSAMDVWGQGT

e 137 Light chain (LC)

MAELTQSPSFLSASVGDRVITICRASQGISNYLAWYQQKPGKAPKLLIYA
ASTLQSGVPSRFSGSGSWTEFTLTISRLQPEDFATYYCQHLNTPWTFG
QGT

15 3. Antibody according to claim 1 being the antibody e301 characterized by having the following sequences of variable parts of the heavy chain and the light chain:

e 301 Heavy chain (HC)

LLEQSGSEVKKPGSSVRVSC TTSGGTLS DYGFNWLRQAPGQGPEWMG
20 GIIPLFRRTTYGQKFQGR LTITADESTGATY MELSSLRSDDTAVYYCARE
KVS VLTGGKSLHYFEYWGKGT

e 301 Light chain (LC)

MAELTQSPATLSVSPGERATLSCRASQSVSSRLAWYQQKRGQAPSLLIY
DTSSRATGVPARFSASGSGTQFTLTIS SLQSEDFALYYCQQYNDWPSTF
25 GQGT

4. Composition for anti-HCV therapy comprising in a therapeutically effective amount at least one of the antibodies according to the preceding claims.

5. Composition according to claim 4 for topical use in gel, creme, ointment
30 and ovule formulations.

6. Use of the antibody according to claims 1-3 for validating anti-HCV vaccines.

7. Nucleic acid coding for antibody according to one of claims from 1 to 3.
8. Recombinant expression vector comprising nucleic acid according to claim 7, able to effectively express the antibody of claims 1 to 3 in prokaryote or in eukaryote cells.
- 5 9. Recombinant vector according to claim 8 further comprising a nucleotide sequence coding for a signal peptide, substantially contiguous with the sequence coding for the antibody of claims from 1 to 3, able to export this antibody out of the cell environment.
- 10 10. Use of the recombinant vector according to claim 9 in gene therapy.
- 10 11. Method for the determination of the presence of antibodies directed against different epitopes of the HCV E2 protein in a biological fluid comprising the steps of:
 - a) determining the presence of antibodies in said fluid able to inhibit the binding of specific human Fab directed against different epitopes of protein
 - 15 E2;
 - b) correlating the presence of so titered antibodies with clinical characteristics of patients, such as prognosis, responsiveness to therapy, infectivity.

1/7




FIGURE 1




FIGURE 2A




FIGURE 2B

4/7




FIGURE 3A




FIGURE 3B

6/7




FIGURE 3C

7/7




FIGURE 4

burioni.ST25.txt
SEQUENCE LISTING

<110> Burioni, Roberto

<120> HUMAN MONOCLONAL ANTIBODY FAB FRAGMENTS DIRECTED AGAINST HCV E2
GLYCOPROTEIN AND ENDOWED WITH IN VITRO NEUTRALIZING ACTIVITY

<130> 30068

<150> IT RM2002A/000049

<151> 2002-01-30

<160> 24

<170> PatentIn version 3.1

<210> 1

<211> 119

<212> PRT

<213> Homo sapiens

<400> 1

Leu Leu Glu Gln Ser Gly Ala Glu Val Lys Met Pro Gly Ala Thr Val
1 5 10 15Lys Val Ser Cys Gln Ser Ser Arg Tyr Thr Phe Thr Ser Tyr Gly Ile
20 25 30Gly Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp
35 40 45Ile Ser Gly Tyr Thr His Glu Thr Lys Tyr Ala Gln Ser Phe Gln Gly
50 55 60Arg Val Thr Met Thr Ala Glu Thr Ser Thr Gly Thr Ala Tyr Met Glu
65 70 75 80Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Thr Tyr Tyr Cys Ala Arg
85 90 95Asp Gly Gly Gly Arg Val Val Val Pro Pro Thr His Leu Arg Ala Phe
Pagina 1

burioni.ST25.txt

100 105 110

Asp Val Trp Gly Gln Gly Thr
115

<210> 2

<211> 104

<212> PRT

<213> Homo sapiens

<400> 2

Met Ala Glu Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser His Arg Val Asn Asn Asn
20 25 30

Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45

Ile Ser Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80

Pro Asp Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Asp Ser Pro
85 90 95

Leu Tyr Ser Phe Gly Gln Gly Thr
100

<210> 3

<211> 124

<212> PRT

<213> Homo sapiens

<400> 3

Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Thr Leu Ser
1 5 10 15

Leu Thr Cys Thr Val Ser Gly Val Ser Ile Ser Tyr Gly Gly Arg Gly
20 25 30

Val Ser Tyr Trp Gly Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu

Pagina 2

burioni.ST25.txt

35	40	45
Trp 50	Ile 55	Phe 60
Leu 65	Asn 70	Ser 75
Ser	Leu 85	Val 90
Cys	Ala 100	Gln 105
Ala	Tyr 115	Phe 120

<210>	4
<211>	102
<212>	PRT
<213>	Homo sapiens

<400> 4

[illegible]

$\langle 210 \rangle$	5
$\langle 211 \rangle$	116
$\langle 212 \rangle$	PRT

burioni.ST25.txt

<213> Homo sapiens

<400> 5

Leu Leu Glu Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val
 1 5 10 15

Lys Val Ser Cys Lys Ala Ser Gly Asp His Tyr Gly Ile Asn Trp Val
 20 25 30

Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro
 35 40 45

Val Phe Gly Thr Thr Thr Tyr Ala Gln Lys Phe Gln Gly Arg Ala Thr
 50 55 60

Ile Thr Ala Asp Asp Ser Thr Gly Thr Ala Phe Leu Glu Leu Thr Arg
 65 70 75 80

Leu Thr Phe Asp Asp Thr Ala Val Tyr Phe Cys Ala Thr Pro His Gln
 85 90 95

Leu His Val Leu Arg Gly Gly Lys Ala Leu Ser Pro Trp Asp Tyr Trp
 100 105 110

Gly Gln Gly Thr
 115

<210> 6

<211> 102

<212> PRT

<213> Homo sapiens

<400> 6

Met Ala Glu Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
 1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
 20 25 30

Leu Ala Trp Tyr Gln Gln Lys Arg Gly Gln Ala Pro Ser Leu Leu Ile
 35 40 45

Tyr Gly Thr Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
 Pagina 4

burioni.ST25.txt

65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asp Trp Pro Ser
85 90 95

Thr Phe Gly Gln Gly Thr
100

<210>	7
<211>	120
<212>	PRT
<213>	Homo sapiens

<400> 7

Leu Leu Glu Gln Ser Gly Ser Glu Val Lys Val Pro Gly Ser Ser Leu
1 5 10 15

Lys Val Ser Cys Lys Thr Ser Gly Gly Thr Phe Ser Thr Tyr Thr Phe
20 25 30

Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly
35 40 45

Ile Thr Pro Ile Ile Gly Ile Ala Asn Tyr Ala Arg Asn Phe Gln Asp
50 55 60

Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Val Tyr Met Glu
65 70 75 80

Val Arg Arg Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys
85 90 95

Thr Ser Glu Val Thr Ala Thr Arg Gly Arg Thr Phe Phe Tyr Ser Ala
100 105 110

Met Asp Val Trp Gly Gln Gly Thr
115 120

<210>	8
<211>	102
<212>	PRT
<213>	Homo sapiens

<400> 8
Met Ala Glu Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
Pagina 5

burioni.ST25.txt

1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr
 20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45

Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Trp Thr Glu Phe Thr Leu Thr Ile Ser Arg Leu Gln Pro
 65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Leu Asn Thr Tyr Pro Trp
 85 90 95

Thr Phe Gly Gln Gly Thr
 100

<210> 9

<211> 118

<212> PRT

<213> Homo sapiens

<400> 9

Leu Leu Glu Gln Ser Gly Ser Glu Val Lys Lys Pro Gly Ser Ser Val
 1 5 10 15

Arg Val Ser Cys Thr Thr Ser Gly Gly Thr Leu Ser Asp Tyr Gly Phe
 20 25 30

Asn Trp Leu Arg Gln Ala Pro Gly Gln Gly Pro Glu Trp Met Gly Gly
 35 40 45

Ile Ile Pro Leu Phe Arg Arg Thr Thr Tyr Gly Gln Lys Phe Gln Gly
 50 55 60

Arg Leu Thr Ile Thr Ala Asp Glu Ser Thr Gly Ala Thr Tyr Met Glu
 65 70 75 80

Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg
 85 90 95

Glu Lys Val Ser Val Leu Thr Gly Gly Lys Ser Leu His Tyr Phe Glu
 100 105 110

Tyr Trp Gly Lys Gly Thr

burioni.ST25.txt

115

<210> 10

<211> 102

<212> PRT

<213> Homo sapiens

<400> 10

Met Ala Glu Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
 1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Arg
 20 25 30

Leu Ala Trp Tyr Gln Gln Lys Arg Gly Gln Ala Pro Ser Leu Leu Ile
 35 40 45

Tyr Asp Thr Ser Ser Arg Ala Thr Gly Val Pro Ala Arg Phe Ser Ala
 50 55 60

Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
 65 70 75 80

Glu Asp Phe Ala Leu Tyr Tyr Cys Gln Gln Tyr Asn Asp Trp Pro Ser
 85 90 95

Thr Phe Gly Gln Gly Thr
 100

<210> 11

<211> 118

<212> PRT

<213> Homo sapiens

<400> 11

Leu Leu Glu Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val
 1 5 10 15

Lys Val Ser Cys Lys Thr Ser Gly Asp Thr Phe Arg Tyr Gly Ile Thr
 20 25 30

Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gln Ile
 35 40 45

Met Pro Thr Phe Ala Thr Ala Thr Tyr Ala Gln Arg Phe Gln Gly Arg
 Pagina 7

[illegible]

<210> 12

<211> 102

<212> PRT

<213> Homo sapiens

<400> 12

Met Ala Glu Leu Thr Gln Ser Pro Ala Thr Leu Ser Ala Ser Pro Gly
1 5 10 15

Glu Arg Ala Ser Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45

Ser Gly Ala Ser Thr Arg Ala Thr Gly Val Pro Ala Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro
85 90 95

His Phe Gly Gln Gly Thr
100

<210> 13

<211> 357

<212> DNA

<213> Homo sapiens

burioni.ST25.txt

<400> 13
 ctgctcgagc agtctggagc tgaggatgaag atgcctgggg ccacagtga ggtctcctgc 60
 cagtcttccc gttacacctt caccagttac ggtatcggct ggggtgagaca ggcccctgga 120
 caggggcttg agtggatggg atggatcagc ggatacacc atgagacaaa atatgcacag 180
 agtttccagg gcagagtcac catgaccgca gagacatcca cgggcacagc gtatatggag 240
 ttgaggagcc tgcgggtctga cgacacggcc acatattact gcgcgagaga tggaggaggg 300
 aggggtggtag tgccgcctac tcatctacgt gctttttagt tctgggggtca agggacg 357

<210> 14

<211> 312

<212> DNA

<213> Homo sapiens

<400> 14
 atggccgagc tcacccagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc 60
 ctctcctgca gggccagtca cagagtcaat aacaacttct tagcctggta tcagcagaaa 120
 cctggccagg ctcccaggct cctcatctct ggtgcatcta ccagggccac tggcatccca 180
 gacaggttca gtggcagtgg gtctggaaca gacttcactc tcaccatcag cagactggag 240
 cctgatgatt ttgcagttta ttattgtcag cagtatgggtg actcacctct ttattctttt 300
 ggccagggga cc 312

<210> 15

<211> 372

<212> DNA

<213> Homo sapiens

<400> 15
 ctgctcgagt ctggcccagg actggtgaag ccttcacaga ccctgtccct cacctgcacc 60
 gtctccggtg tctccatcag ttacggtggt cgtggcggtt cctactgggg ttgggtccgc 120
 cagtccccag ggaagggcct ggagtggatt ggccacatct actactttgg agacaccttc 180
 tacaaccctg ccctcaacaa tcgagctacc atatcaatag actcatcaa aaaccagttc 240
 tccctcaagc tcaagtctgt gactgcctca gacacggccc tgtatttctg tgccaggagc 300
 accctacagt attttgactg gttattgaca cgggaggctg cctactccat tgacttctgg 360
 ggccagggaa ta 372

<210> 16

<211> 306

burioni.ST25.txt

<212> DNA

<213> Homo sapiens

<400> 16

```

atggccgagc tcacccagtc tccatccttc ctgtctgcat ctgttgagga ccgagtcacc    60
atcacttgcc gggccagtca gggcgtcacc attcttttag cctgggtatca gcaaaagcca    120
gggaaacccc ctaaggccct gatttatgct gcatcgtctt tgcaaagtgg ggtcccatca    180
aggttcagcg gcagtgggtc tgacacagat ttactctca caatcagcag cctacagcct    240
gaagattctg caacttatta ctgtcaacaa cttaacactt acccgtggac gttcggccag    300
gggacc                                           306

```

<210> 17

<211> 348

<212> DNA

<213> Homo sapiens

<400> 17

```

ctgctcgagc agtcaggggc tgaggtgaag aagcctgggt cctcggtgaa ggtctcctgc    60
aaggcttctg gagaccacta tgggtatcaac tgggtgacgac agggccctgg acaagggctg    120
gagtggatgg gcggtatcat ccctgtcttt ggcacaacta cctacgcaca gaagttccag    180
ggcagagcca ccattaccgc ggacgactcc acggggacgg cttttttgga gctgaccaga    240
ctgacatttg acgacacggc cgtctatttc tgtgacgacac ctcaccaact gcatgtcctc    300
cggggcggtg aagccctctc cccctgggac tactggggcc aggggaacc                348

```

<210> 18

<211> 306

<212> DNA

<213> Homo sapiens

<400> 18

```

atggccgagc tcacccagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc    60
ctctcctgca gggccagtca gagtgttagc agtaacttag cctgggtacca gcagaaacgt    120
ggccaggctc ccagtctcct catctacgga acatctacca gggccactgg tatcccagcc    180
aggttcagtg gcagtgggtc tgggacagag ttactctca ccatcagcag cctgcagtct    240
gaagattttg cagtttatta ctgtcagcag tataatgatt ggccctccac cttcggccaa    300
gggaca                                           306

```


burioni.ST25.txt

<210> 19

<211> 360

<212> DNA

<213> Homo sapiens

<400> 19

ctgctcgagc agtctgggtc tgaagtaaaa gtgcccgggt cctcgttgaa ggtctcctgc	60
aagacttctg gaggcacctt cagcacctat actttcagct ggggtgcgaca ggcccctgga	120
cagggacttg agtggatggg ggggatcacc cctatcattg gcatcgcaaa ctacgcacgg	180
aacttccagg acagagtcac catcacccgc gacgaatcca cgagcacggt ctacatggag	240
gtgaggaggc tgagatctga ggacacggcc gtatattatt gtgcgaaaac ttcggaagta	300
acagccacta gagggcggac tttcttctac tccgctatgg acgtctgggg tcaagggacc	360

<210> 20

<211> 306

<212> DNA

<213> Homo sapiens

<400> 20

atggccgagc tcaccagtc tccatccttc ctgtctgcat ctgtaggaga cagagtcacc	60
atcacttgcc gggccagtca gggcataagc aattatttag cctgggtatca gcaaaaacca	120
gggaaagccc ctaagctcct gatctatgct gcatccactt tgcaaagtgg ggtcccatcg	180
aggttcagcg gcagtggatc ttggacagaa ttactctca caatcagccg cctccagcct	240
gaagattttg caacttatta ctgtcaacac cttaatactt acccgtaggac gttcggccaa	300
gggacc	306

<210> 21

<211> 354

<212> DNA

<213> Homo sapiens

<400> 21

ctgctcgagc agtctgggtc tgaggtgaag aaacctgggt cctcggtgag ggtctcgtgc	60
acgacttctg gaggcacctt gagcgactat ggtttcaact gggtacgaca ggcccctgga	120
caagggcctg agtggatggg agggatcatc ctttgtttc gaagaacaac ctacggacag	180
aagttccagg gcagactcac cattaccgcg gacgagtcca cgggcgcaac ctacatggag	240

burioni.ST25.txt

ctgagcagcc tgagatctga cgacacggcc gtctattact gtgcgagaga gaaagtttcg	300
gtcctcacag gcggaaagtc actccattac tttgaatatt ggggcaaggg aacc	354

<210> 22

<211> 306

<212> DNA

<213> Homo sapiens

<400> 22	
atggccgagc tcacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc	60
ctctcctgca gggccagtca gagggttagc agcagggttag cctggtacca gcagaaacgt	120
ggccaggctc ccagtctcct catctatgac acatcttcca gggccactgg tgtcccagcc	180
aggttcagtg ccagtgggtc tgggacgcag ttactctca ccatcagcag cctgcagtct	240
gaagattttg cactttatta ctgtcagcag tataatgatt ggccctccac cttcggccaa	300
gggaca	306

<210> 23

<211> 354

<212> DNA

<213> Homo sapiens

<400> 23	
ctgctcgagg agtctggggc tgaggtgaag aagccagggt cctcggtgaa ggtctcctgc	60
aagacttctg gagacacctt cagatatggt atcacgtggg tgcgacaggc ccctggacaa	120
gggcttgagt ggatgggaca gatcatgcct acgtttgcga cagcaaccta cgcacagagg	180
ttccagggca gagtcacgat ttccgcggac gaatccacga gcacagccta cttggagggtg	240
cgcagcctga gatctgaaga cacggccgtc tattactgtg cgacacctcg ccaagttact	300
atacttcggg gacctaaagc cctctcccct tgggactact ggggcccaggg aacc	354

<210> 24

<211> 306

<212> DNA

<213> Homo sapiens

<400> 24	
atggccgagc tcacccagtc tccagccacc ctgtctgcgt ctccagggga aagagcctcc	60
ctctcctgca gggccagtca gagggttagt agcaacttag cctggtacca gcagaaacct	120

burioni.ST25.txt

ggccaggctc ccaggctcct catctctggt gcatccacca gggccactgg tgtcccggcc	180
aggttcagtg gcagtgggtc tgggacagag ttcactctca ccatcagtag cctgcagtct	240
gaagattttg cagtttatta ctgtcagcag tataataact ggcctcccca ctttggccag	300
gggacc	306